Loading patent…
AssigneeIncept, LLC
InventorsAmarpreet S. Sawhney, Arthur Driscoll, Charles D. Blizzard, Ankita D. Desai, Peter Jarrett
Estimating the term…
Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.
An intracameral depot composition comprising a biocompatible xerogel and hydrolytically degradable particles that are embedded in the biocompatible xerogel wherein the xerogel comprises a matrix having covalent crosslinks between one or more multiple-arm polyethylene glycol (PEG) precursors, wherein the matrix of the xerogel has a dry weight that is at least 30% of a sum of the dry weight of the xerogel matrix and a dry weight of the hydrolytically degradable particles, with the xerogel being a biocompatible hydrogel after exposure to intraocular fluid and the biocompatible hydrogel being hydrolytically degradable, wherein the hydrolytically degradable particles comprise the therapeutic agent and a hydrolytically degradable polymer material which comprises one or more of polylactic acid (PLA), polyglycolic acid (PGA), and a copolymer of PLA and PGA, and wherein the hydrolytically degradable particles hydrolytically degrade in an intracameral site of an eye to provide a controlled release of the therapeutic agent for use in the treatment of an ocular disease.
Dependencies are inferred from the claim text.